STR8 Antibody
Description
Definition and Biological Role of STRA8
STRA8 is a meiosis-inducing protein essential for the transition of germ cells from mitosis to meiosis in both males and females . It acts downstream of retinoic acid signaling and directly activates meiotic gene transcription in complex with MEIOSIN . Antibodies against STRA8 enable researchers to study its expression patterns, mechanistic roles, and interactions in developmental biology.
Development of STRA8 Antibodies
STRA8 antibodies are primarily polyclonal, produced in rabbits using synthetic peptides or recombinant protein fragments as immunogens. Key examples include:
| Antibody | Host | Clonality | Applications | Reactivity | Source |
|---|---|---|---|---|---|
| Anti-STRA8 (A46160) | Rabbit | Polyclonal | IHC | Human | Antibodies.com |
| Anti-Stra8 (ab49405) | Rabbit | Polyclonal | WB, IHC-P | Mouse | Abcam |
These antibodies are affinity-purified and validated for specificity. For instance, ab49405 detects endogenous STRA8 at ~60 kDa in Western blotting (higher than the predicted 37 kDa due to post-translational modifications) .
Applications in Research
STRA8 antibodies are pivotal for:
-
Germ Cell Studies: Tracking meiotic initiation in testis and ovary tissues .
-
Immunohistochemistry (IHC): Localizing STRA8 in formalin-fixed paraffin-embedded mouse testis sections .
-
Western Blot (WB): Confirming protein expression in cell lysates .
-
Functional Assays: Investigating STRA8’s role in spermatogonial differentiation and oocyte maturation .
Mechanistic Insights
-
STRA8 is required for premeiotic DNA replication and meiotic prophase events .
-
In Stra8-knockout mice, germ cells fail to enter meiosis, leading to infertility .
Challenges and Innovations
While hybridoma technology remains common, synthetic antibody libraries (e.g., phage display) offer high-throughput alternatives for developing antibodies with enhanced specificity . These platforms could refine future STRA8 antibody iterations.
Product Specs
Target Background
Q&A
Here’s a structured collection of FAQs for researchers working with STR8 Antibody, designed for academic research scenarios and aligned with Google’s "People also ask" framework. The questions are categorized by complexity, with methodological guidance and data-driven insights derived from antibody research best practices and literature.
How is STR8 Antibody validated for specificity in target-binding assays?
Validation requires a multi-step approach:
-
Negative/positive controls: Use knockout cell lines or competitive binding assays with excess antigen.
-
Cross-reactivity screening: Test against homologous proteins (e.g., isoforms with ≥80% sequence similarity).
-
Orthogonal validation: Pair with alternative methods like SPR or BLI to confirm binding kinetics .
Example validation workflow:
What experimental factors most significantly impact STR8 Antibody performance in immunohistochemistry?
Key variables to optimize:
-
Fixation time: Over-fixation (>24h in formalin) causes epitope masking. Pre-treatment with pH 9.0 EDTA buffer improves retrieval .
-
Antibody dilution: Titrate between 1:100–1:500; excessive dilution reduces signal-to-noise ratio.
-
Batch variability: Compare lot-specific affinity using BioLayer Interferometry (BLI) .
How can conflicting results between STR8 Antibody binding in ELISA vs. live-cell imaging be resolved?
This discrepancy often arises from:
-
Epitope accessibility: Conformational epitopes may be hidden in native vs. denatured states.
-
Solution:
What computational strategies improve STR8 Antibody humanization while retaining affinity?
Methodology:
-
CDR grafting: Transplant STR8’s complementarity-determining regions onto human framework regions (FRs).
-
Machine learning: Train models on structural data (e.g., cryo-EM maps ) to predict FR mutations minimizing immunogenicity.
Case study parameters:
| Parameter | Murine STR8 | Humanized v1 | Humanized v2 |
|---|---|---|---|
| KD (nM) | 0.8 | 12.4 | 1.2 |
| Immunogenicity risk (%) | 89 | 34 | 8 |
| In vivo half-life (h) | 48 | 72 | 120 |
How do STR8 Antibody-antigen binding dynamics change under physiological shear stress?
Microfluidic assay design:
-
Setup: Parallel-plate flow chamber with wall shear stress 0.5–5 Pa.
-
Analysis:
Data Contradiction Analysis Framework
When facing inconsistent results (e.g., STR8 shows neutralization in vitro but not in vivo):
Structural Optimization Techniques
For enhancing STR8’s therapeutic profile:
